Skip to content
HyperSlot Network

{‘She possesses little expertise’: the US healthcare community prepares for Høeg's role at the Food and Drug Administration.

Given that America proceeds with unprecedented revisions to its vaccination schedules, one figure appears unexpectedly: Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccinations in the global health crisis and has concentrated on possible deaths following Covid immunization in her short tenure at the Food and Drug Administration.

Scheduled Changes to Pediatric Immunization Schedule

Public health authorities planned to unveil sweeping revisions to the pediatric immunization program earlier this month, bringing the US with the Danish vaccine program, according to reports – a major change that would place the US at odds with many the world with little proof for benefit. The announcement has been postponed until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to present at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to head the division this calendar year.

A Shift at the Agency

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a renewed priority upon rolling back previously authorized vaccines at the FDA.

The new acting director has frequently advocated for halting certain childhood shot schedules in the US to become more like Denmark's approach, a nation with comprehensive healthcare and a population roughly the population of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccination policy – usually the responsibility of Prasad, head of the FDA’s CBER – rather than medication approval.

Questions Over Expertise

Dr. Høeg has no obvious background in pharmaceutical research, regulation or leadership, which has been typical for previous directors of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, stated Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in managing a major agency. She has no expertise in industry regulation.”

Past commissioners of CBER would “be deeply familiar with regulatory frameworks and the research of drug development”, noted a former acting FDA commissioner. “Frankly, she lacks the type of experience that previous people who ran CBER have had.”

This division has an immense workload at the FDA, the former commissioner emphasized.

“Many people just zeroes in on the new drug program, but the generic program authorizes thousands of generic drugs. There’s a biosimilars division, over-the-counter program and other areas, and each of these have to be managed,” she noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

There is also, a substantial management component to the position, which supervises in excess of 5,000 personnel. “It is a huge leadership role, if you perform it correctly,” the former official added.

Official Statement and Contentious Policies

When asked about questions about Dr. Høeg's fitness for the role and whether this assignment indicates more teamwork among agency officials on immunizations, a representative responded that the “questions rely on inaccurate presumptions”.

“Her resume aligns with the functions of her job,” the representative said, pointing to the time Dr. Høeg spent counseling the agency head on “medication safety and approval science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg takes over the agency head's controversial fast-track approval initiative, a disputed rapid therapy clearance system that allegedly worried her former heads. “By what process are these drugs being selected for this fast-track system? Who is making the calls?” Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

In general, he remarked, “the agency seems to be moving towards less stringent rules of all drugs, except for immunizations.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if troubling, history, critics said. She published a study using unverified volunteer-provided data to determine the frequency of myocarditis after Covid immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the new administration included revising regulations for recently developed shots and halting “optional” immunizations, she remarked following the vote on a podcast. At the agency, Dr. Høeg has allegedly floated the idea of excluding teenage boys from receiving COVID-19 vaccines.

“She’s an thorough true believer who starts off with her preconceived notions and reverse-engineers to retrofit the data in a highly misleading, fraudulent manner,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|

About the author

Mrs. Jamie Hopkins MD

A software engineer and tech writer passionate about AI, cybersecurity, and open-source projects, with over a decade of industry experience.

HyperSlot Network

Type to search articles.